RNA Avidity Net Sales Margin

Corporate emblem and logo of Avidity (RNA)

Avidity Biosciences (RNA) is achieving a breakthrough in the development of AOC conjugates to combat muscular dystrophies. Net profit returns from sales visualize this growth, where the -180.90 level represents the current value. Stability is ensured by the diversification of the rare pathology portfolio, while sustainable development is based on strict bioethical standards and environmental control of laboratories.

Avidity Biosciences (RNA) - Net Margin from 07/04/2022 to 11/19/2026

Analytical breakdowns and data insights for company Avidity (RNA)

- share price and expert price forecast:
Comprehensive company analysis:Avidity Biosciences
Flagship merchandise of Avidity Biosciences Inc

The net profitability of Avidity Biosciences (RNA) reflects the portion of profit remaining after deducting all operating expenses and taxes from revenue, which is critical given the high labor costs for physicians and scientists. By analyzing the company's net margin, an investor can assess how effectively the automation of RNA therapy synthesis offsets the cost of clinical trials to ensure the long-term financial sustainability of the business.

Competitors of Avidity Biosciences (RNA)

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin CRSP|Company Sales Margin GeneDx|Net Margin Ultragenyx RARE|Company Sales Margin Beam Therapeutics (BEAM)|SRPT: Return on Sales by Net Profit|Net Margin Twist Bioscience|TXG (10x Genomics) - Return on Sales by Net Profit|Intellia Therapeutics, Inc. (NTLA) - Net Sales Margin|Net Margin Stoke Therapeutics Inc|BLFS: Net Profit Rate|Return on Sales by Net Profit WVE (Wave Life Sciences Corp)|Company Sales Margin Maze Therapeutics Corp|Sionna Therapeutics Inc - Return on Sales by Net Profit|PRME (primemedicine.com) - Net Profit Margin|TSHA - Net Margin|QURE (uniQure) - Net Return on Sales|MeiraGTx Corp (MGTX) - Net Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX